The emergence of SARS-CoV-2 as a global threat to human health has highlighted the need for the development of novel therapies targeting current and emerging coronaviruses with pandemic potential. The coronavirus main protease (M(pro), also called 3CL(pro)) is a validated drug target against coronaviruses and has been heavily studied since the emergence of SARS-CoV-2 in late 2019. Here we report the biophysical and enzymatic characterization of native M(pro), then characterize the steady-state kinetics of several commonly used fluorescence resonance energy transfer (FRET) substrates, fluorogenic substrates, and 6 of the 11 reported SARS-CoV-2 polyprotein cleavage sequences. We then assessed the suitability of these substrates for high throughput screening. Guided by our assessment of these substrates, we developed an improved 5-carboxyfluorescein-based FRET substrate which is better suited for high throughput screening and is less susceptible to interference and false positives than existing substrates. This study provides a useful framework for the design of coronavirus M(pro) enzyme assays to facilitate the discovery and development of therapies targeting M(pro).
Improved SARS-CoV-2 main protease high throughput screening assay using a 5-carboxyfluorescein substrate